Croft-Leominster’s Gilead Sciences GILD Stock Holding History

Croft-Leominster’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$700K	Sell	9,777 -47,996	-83%	-$3.64M	0.66%	48
2017 Q3	$4.68M	Sell	57,773 -944	-2%	-$72.2K	1.11%	38
2017 Q2	$4.16M	Sell	58,717 -137	-0.2%	-$9.12K	0.98%	46
2017 Q1	$4M	Buy	+58,854	New	+$4.14M	0.95%	44
2016 Q4	–	Sell	-94,903	Closed	-$7.05M	–	42
2016 Q3	$7.51M	Sell	94,903 -6,152	-6%	-$500K	1.86%	12
2016 Q2	$8.43M	Sell	101,055 -557	-0.5%	-$49.4K	1.89%	9
2016 Q1	$9.33M	Buy	101,612 +22,673	+29%	+$2.04M	2.12%	6
2015 Q4	$7.99M	Sell	78,939 -1,399	-2%	-$146K	1.72%	11
2015 Q3	$7.89M	Buy	80,338 +51,636	+180%	+$5.73M	1.82%	10
2015 Q2	$3.36M	Buy	+28,702	New	+$3.14M	0.65%	60

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Croft-Leominster's GILD Position: Q4 2017 in Review

Croft-Leominster reduced its Gilead Sciences (GILD) stake by 83% in Q4 2017, selling an estimated $3.64M and leaving 9,777 shares worth $700K. The position accounts for 0.66% of the portfolio, ranked #48.

Croft-Leominster first reported a position in GILD in Q2 2015 and has held it in 10 quarters since. The position peaked at $9.33M in Q1 2016. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

Croft-Leominster held 9,777 shares of Gilead Sciences worth $700K as of Q4 2017.
Croft-Leominster sold 47,996 Gilead Sciences shares in Q4 2017, an estimated $3.64M.
Gilead Sciences made up 0.66% of Croft-Leominster's portfolio in Q4 2017, its #48 holding.
Croft-Leominster first reported a position in Gilead Sciences in Q2 2015 and has held it in 10 quarters since.
Croft-Leominster's Gilead Sciences position peaked at $9.33M in Q1 2016.
1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on Croft-Leominster's 13F filing for Q4 2017, filed 6 Mar 2018.